IMRX
Immuneering Corp
Overview
Immuneering Corp develops Deep Cyclic Inhibitors, a novel class of oral cancer drugs designed to cyclically disrupt tumor cell signaling pathways while sparing healthy cells. The company's lead candidate, atebimetinib, targets the MAPK pathway in solid tumors including pancreatic and lung cancers, and is in late-stage clinical trials.
Immuneering Corp is a Healthcare company operating in Biotechnology with a $287.9M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
2 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q2 FY20262026-08-12EPS— vs $-0.27—Rev— vs ——EODHD
- Q1 FY20262026-05-11EPS$-0.21 vs $-0.35+40.0%Rev— vs ——EODHD
- Q4 FY20252026-03-10EPS$-0.18 vs $-0.31+42.3%Rev$0 vs ——EODHD
- Q3 FY20252025-11-11EPS$-0.38 vs $-0.41+7.3%Rev$0 vs ——EODHD
- Q2 FY20252025-08-12EPS$-0.82 vs $-0.42-95.2%Rev$0 vs ——EODHD
- Q1 FY20252025-05-05EPS$-0.44 vs $-0.49+10.2%Rev$0 vs ——EODHD
- Q4 FY20242025-03-19EPS$-1.07 vs $-0.45-100.0%Rev$726.3K vs ——EODHD
- Q3 FY20242024-11-12EPS$-0.49 vs $-0.55+11.2%Rev$0 vs ——EODHD
- Q2 FY20242024-08-05EPS$-0.47 vs $-0.52+9.6%Rev$0 vs ——EODHD
- Q1 FY20242024-05-06EPS$-0.49 vs $-0.50+2.0%Rev$0 vs ——EODHD
- Q4 FY20232024-02-29EPS$-0.52 vs $-0.47-10.6%Rev$-94.4M vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.43 vs $-0.49+12.2%Rev$0 vs ——EODHD
- Q2 FY20232023-08-02EPS$-0.43 vs $-0.53+18.9%Rev$94.4M vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.51 vs $-0.56+8.9%Rev$0 vs ——EODHD
- Q4 FY20222023-03-05EPS$-0.50 vs $-0.58+13.8%Rev$455 vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.49 vs $-0.490.0%Rev$38.4K vs ——EODHD
- Q2 FY20222022-08-09EPS$-0.44 vs $-0.52+15.4%Rev$94.4K vs ——EODHD
- Q1 FY20222022-05-09EPS$-0.49 vs $-0.45-8.9%Rev$183.7K vs ——EODHD
- Q4 FY20212022-03-09EPS$-0.42 vs $-0.39-7.7%Rev$189.6K vs ——EODHD
- Q3 FY20212021-11-08EPS$-0.47 vs $-0.57+17.5%Rev$482.1K vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | — | $-0.27 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-11 | $-0.21 | $-0.35 | +40.0% | — | — | — | EODHD |
| Q4 FY2025 | 2026-03-10 | $-0.18 | $-0.31 | +42.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.38 | $-0.41 | +7.3% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.82 | $-0.42 | -95.2% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-05 | $-0.44 | $-0.49 | +10.2% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-19 | $-1.07 | $-0.45 | -100.0% | $726.3K | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-0.49 | $-0.55 | +11.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-0.47 | $-0.52 | +9.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.49 | $-0.50 | +2.0% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-29 | $-0.52 | $-0.47 | -10.6% | $-94.4M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.43 | $-0.49 | +12.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.43 | $-0.53 | +18.9% | $94.4M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.51 | $-0.56 | +8.9% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-05 | $-0.50 | $-0.58 | +13.8% | $455 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.49 | $-0.49 | 0.0% | $38.4K | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.44 | $-0.52 | +15.4% | $94.4K | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.49 | $-0.45 | -8.9% | $183.7K | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.42 | $-0.39 | -7.7% | $189.6K | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-0.47 | $-0.57 | +17.5% | $482.1K | — | — | EODHD |
Source: EODHD. IMRX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IMRX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 4 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $1.51 | $1.38 | +9.6% | -6.9% | -5.2% |
| Q4 FY2025 | $1.55 | $1.42 | +8.9% | -1.3% | -3.3% |
| Q3 FY2025 | $1.75 | $1.50 | +16.8% | -2.0% | -1.4% |
| Q2 FY2025 | $1.76 | $1.62 | +8.7% | +0.8% | +1.2% |
| Q1 FY2024 | $1.55 | $1.51 | +2.9% | +0.4% | -1.2% |
| Q4 FY2024 | $1.66 | $1.63 | +1.9% | -5.3% | -3.8% |
| Q3 FY2024 | $1.95 | $1.75 | +11.3% | -3.1% | -1.2% |
| Q2 FY2024 | $1.59 | $1.51 | +5.3% | -2.8% | -3.9% |
| Q1 FY2023 | $1.62 | $1.55 | +4.2% | -0.9% | +0.7% |
| Q4 FY2023 | $1.62 | $1.55 | +4.6% | -1.3% | -0.6% |
Guidance change history
Sample- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
- Q1 FY2024Maintained2024-04-15
- Q4 FY2024Suspended2024-13-15
- Q3 FY2024Raised2024-10-15
- Q2 FY2024Raised2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Benjamin J ZeskindCEO1 yr2 callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance cut Q1 FY2025
- Michael BookmanCHIEF LEGAL OFFICER, SECRETARY8 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/2 beats (100%) • last call held guidance Q2 FY2025
- Mallory MoralesChief Accounting Officer9 mo2 callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance cut Q1 FY2025
- Leah R NeufeldCHIEF PEOPLE OFFICER11 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance cut Q3 FY2025
- Brett Matthew HallCHIEF SCIENTIFIC OFFICER1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last call held guidance Q2 FY2025
- Harold Eugene BrakewoodChief Business Officer1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance raise Q2 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IMRX.
$ curl https://api.spokenalpha.com/v1/companies/IMRXFAQ
Frequently asked about IMRX
Where can I find Immuneering Corp's (IMRX) earnings call transcripts?
Spoken Alpha indexes IMRX's earnings call transcripts at https://spokenalpha.com/companies/IMRX. Each call links to attributed speakers and parsed analyst Q&A. Immuneering Corp's own investor relations page is at https://ir.immuneering.com/investor-relations.
When was Immuneering Corp's most recent earnings call?
Immuneering Corp (IMRX) held its most recent earnings call on 2025-11-12, covering fiscal Q3 2025.
What sector is IMRX in?
Immuneering Corp (IMRX) operates in the Healthcare sector (Biotechnology industry).